CN114588194A - Biological component composition for improving blood viscosity and blood vessel embolism - Google Patents
Biological component composition for improving blood viscosity and blood vessel embolism Download PDFInfo
- Publication number
- CN114588194A CN114588194A CN202210199790.5A CN202210199790A CN114588194A CN 114588194 A CN114588194 A CN 114588194A CN 202210199790 A CN202210199790 A CN 202210199790A CN 114588194 A CN114588194 A CN 114588194A
- Authority
- CN
- China
- Prior art keywords
- parts
- blood
- blood viscosity
- raw materials
- biological component
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004369 blood Anatomy 0.000 title claims abstract description 84
- 239000008280 blood Substances 0.000 title claims abstract description 84
- 208000005189 Embolism Diseases 0.000 title claims abstract description 46
- 210000004204 blood vessel Anatomy 0.000 title claims abstract description 39
- 239000000203 mixture Substances 0.000 title claims abstract description 17
- 239000000284 extract Substances 0.000 claims abstract description 47
- 239000002994 raw material Substances 0.000 claims abstract description 45
- 241000361919 Metaphire sieboldi Species 0.000 claims abstract description 33
- 241000219226 Acer truncatum Species 0.000 claims abstract description 26
- 235000006533 astragalus Nutrition 0.000 claims abstract description 24
- 239000000843 powder Substances 0.000 claims abstract description 23
- 230000002792 vascular Effects 0.000 claims abstract description 22
- 239000003094 microcapsule Substances 0.000 claims abstract description 21
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 20
- 235000001287 Guettarda speciosa Nutrition 0.000 claims abstract description 14
- 241001061264 Astragalus Species 0.000 claims abstract description 12
- 210000004233 talus Anatomy 0.000 claims abstract description 12
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 claims abstract description 11
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract description 11
- 235000013793 astaxanthin Nutrition 0.000 claims abstract description 11
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 claims abstract description 11
- 229940022405 astaxanthin Drugs 0.000 claims abstract description 11
- 239000001168 astaxanthin Substances 0.000 claims abstract description 11
- 239000003814 drug Substances 0.000 claims abstract description 11
- 235000013557 nattō Nutrition 0.000 claims abstract description 11
- 229920002498 Beta-glucan Polymers 0.000 claims abstract description 10
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 10
- 241000168517 Haematococcus lacustris Species 0.000 claims abstract description 10
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 10
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 10
- 239000011718 vitamin C Substances 0.000 claims abstract description 10
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 claims abstract description 9
- 239000004480 active ingredient Substances 0.000 claims abstract description 8
- 239000000463 material Substances 0.000 claims abstract description 8
- 229920001353 Dextrin Polymers 0.000 claims abstract description 4
- 239000004375 Dextrin Substances 0.000 claims abstract description 4
- 229920002472 Starch Polymers 0.000 claims abstract description 4
- 235000013339 cereals Nutrition 0.000 claims abstract description 4
- 235000019425 dextrin Nutrition 0.000 claims abstract description 4
- 229920001592 potato starch Polymers 0.000 claims abstract description 4
- 235000019698 starch Nutrition 0.000 claims abstract description 4
- 239000008107 starch Substances 0.000 claims abstract description 4
- 150000005846 sugar alcohols Chemical class 0.000 claims abstract description 4
- 238000002360 preparation method Methods 0.000 claims description 25
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 17
- 241000382455 Angelica sinensis Species 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 15
- 241000045403 Astragalus propinquus Species 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 12
- 241000125175 Angelica Species 0.000 claims description 11
- 235000013361 beverage Nutrition 0.000 claims description 11
- 230000001684 chronic effect Effects 0.000 claims description 8
- 230000010102 embolization Effects 0.000 claims description 8
- 235000019198 oils Nutrition 0.000 claims description 8
- 239000002775 capsule Substances 0.000 claims description 7
- 230000008569 process Effects 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 5
- 235000013305 food Nutrition 0.000 claims description 5
- 238000007689 inspection Methods 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 5
- 206010014513 Embolism arterial Diseases 0.000 claims description 4
- 229940107666 astragalus root Drugs 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 210000003462 vein Anatomy 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 2
- 230000008901 benefit Effects 0.000 abstract description 5
- 230000036770 blood supply Effects 0.000 abstract description 5
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 5
- 230000036541 health Effects 0.000 abstract description 5
- 208000010110 spontaneous platelet aggregation Diseases 0.000 abstract description 4
- 230000036772 blood pressure Effects 0.000 abstract description 3
- 210000004556 brain Anatomy 0.000 abstract description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 abstract description 3
- 230000002708 enhancing effect Effects 0.000 abstract description 2
- 244000061520 Angelica archangelica Species 0.000 abstract 3
- 230000000694 effects Effects 0.000 description 17
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 9
- 230000017531 blood circulation Effects 0.000 description 9
- GWHCXVQVJPWHRF-KTKRTIGZSA-N (15Z)-tetracosenoic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCCCC(O)=O GWHCXVQVJPWHRF-KTKRTIGZSA-N 0.000 description 8
- 208000026106 cerebrovascular disease Diseases 0.000 description 8
- 241001233061 earthworms Species 0.000 description 8
- 230000002526 effect on cardiovascular system Effects 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 208000024172 Cardiovascular disease Diseases 0.000 description 6
- 229920000881 Modified starch Polymers 0.000 description 6
- 239000004368 Modified starch Substances 0.000 description 6
- GWHCXVQVJPWHRF-UHFFFAOYSA-N cis-tetracosenoic acid Natural products CCCCCCCCC=CCCCCCCCCCCCCCC(O)=O GWHCXVQVJPWHRF-UHFFFAOYSA-N 0.000 description 6
- 235000019426 modified starch Nutrition 0.000 description 6
- XJXROGWVRIJYMO-SJDLZYGOSA-N Nervonic acid Natural products O=C(O)[C@@H](/C=C/CCCCCCCC)CCCCCCCCCCCC XJXROGWVRIJYMO-SJDLZYGOSA-N 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 208000029078 coronary artery disease Diseases 0.000 description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- 244000063299 Bacillus subtilis Species 0.000 description 3
- 235000014469 Bacillus subtilis Nutrition 0.000 description 3
- 206010008190 Cerebrovascular accident Diseases 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- 239000009636 Huang Qi Substances 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 201000001421 hyperglycemia Diseases 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 238000002791 soaking Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 235000001465 calcium Nutrition 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000003113 dilution method Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000019152 folic acid Nutrition 0.000 description 2
- 229960000304 folic acid Drugs 0.000 description 2
- 239000011724 folic acid Substances 0.000 description 2
- 108010070324 lumbrokinase Proteins 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000000518 rheometry Methods 0.000 description 2
- 238000010008 shearing Methods 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 2
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 206010069729 Collateral circulation Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 241000243686 Eisenia fetida Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108010088842 Fibrinolysin Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- PFRQBZFETXBLTP-UHFFFAOYSA-N Vitamin K2 Natural products C1=CC=C2C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C(=O)C2=C1 PFRQBZFETXBLTP-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000005465 channeling Effects 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000013332 literature search Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- DKHGMERMDICWDU-GHDNBGIDSA-N menaquinone-4 Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 DKHGMERMDICWDU-GHDNBGIDSA-N 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 229940086319 nattokinase Drugs 0.000 description 1
- 108010073682 nattokinase Proteins 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000000643 oven drying Methods 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- -1 oxygen ions Chemical class 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009044 synergistic interaction Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019143 vitamin K2 Nutrition 0.000 description 1
- 239000011728 vitamin K2 Substances 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/20—Aceraceae (Maple family)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L11/00—Pulses, i.e. fruits of leguminous plants, for production of food; Products from legumes; Preparation or treatment thereof
- A23L11/50—Fermented pulses or legumes; Fermentation of pulses or legumes based on the addition of microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/385—Concentrates of non-alcoholic beverages
- A23L2/39—Dry compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Physiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Agronomy & Crop Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to the technical field of medicine and health care products, and discloses a biological component composition for improving blood viscosity and vascular embolism, which comprises the following active component raw materials in parts by weight: 1-20 parts of acer truncatum buge oil microcapsule powder, 1-20 parts of earthworm extract, 1-20 parts of natto, 0.1-5 parts of astaxanthin (haematococcus pluvialis), 0.1-1 part of yeast beta-glucan, 0.02-1.2 parts of vitamin C, 0.5-6 parts of astragalus and angelica extract and auxiliary materials accounting for 0-20% of the total weight of the active ingredient raw materials, wherein the proportion of the astragalus and the angelica in the astragalus and angelica extract is 1:1, and the auxiliary materials can be one or more of cereal starch, potato starch, dextrin and sugar alcohol. The biological component composition for improving the blood viscosity and the vascular embolism has the advantages of obviously reducing serum cholesterol and triglyceride, reducing blood pressure, enhancing the blood supply of heart and brain, softening blood vessels, reducing platelet aggregation and the like, and solves the problems of the blood viscosity and the vascular embolism.
Description
Technical Field
The invention relates to the technical field of medicine and health care products, in particular to a biological component composition for improving blood viscosity and vascular embolism.
Background
The term "blood viscosity" is medically called hyperviscosity. The blood viscosity is one of the important factors for forming the blood flow resistance, the blood circulation is not smooth, the blood flow speed is reduced, the blood cells can be overlapped and gathered, and the peripheral blood vessel blockage is easily formed. Many diseases are related to blood viscosity, and people with cardiovascular and cerebrovascular diseases have blood viscosity which is several times higher than that of normal people, and often the indexes of blood rheology are abnormal before no obvious clinical symptoms exist. It is known that hypertension, hyperglycemia, hyperlipidemia and hyperglycemia are high risk factors for inducing cardiovascular and cerebrovascular diseases, and the harm of blood viscosity to health is no less than 'four high', improving blood viscosity, preventing and treating the formation of vascular embolism, which has very important significance for early treatment of cardiovascular and cerebrovascular diseases.
The phenomenon of blocking the lumen of a blood vessel by abnormal substances insoluble in blood appearing in circulating blood and traveling to a distant place with the blood flow is called embolism, and common types of embolism include thromboembolism, lipoembolism and the like. The main cause of vascular embolism is hyperviscosity. Blood becomes sticky, thick and coagulated, which leads to insufficient blood supply of coronary artery and arteriosclerosis of blood vessels, so that blood in the blood vessels is coagulated, the blood vessels are plugged into lumens, blood flow cannot pass through the lumens, and the blood vessels are plugged. The vascular embolism can cause ischemia necrosis of blood supply organs, and cause the occurrence of myocardial infarction and cerebral infarction diseases, thereby endangering life and health.
At present, the reduction of blood viscosity mainly adopts a physical dilution method and a drug therapy method, wherein the former method is to introduce a certain amount of liquid medicine into blood vessels to dilute blood so as to reduce the blood viscosity, and the dilution method can quickly reduce the blood viscosity, but the curative effect retention time is short, and the treatment is troublesome; the latter is oral administration of various Chinese and western medicines such as nicotinic acid medicine, and most oral medicines can not achieve satisfactory curative effect. Therefore, it is necessary to develop new products effective in reducing blood viscosity and improving vascular embolization.
Therefore, the invention discloses a biological component composition for improving blood viscosity and vascular embolism, which can obviously reduce serum cholesterol and triglyceride, reduce blood pressure, enhance the blood supply of heart and brain, soften blood vessels and reduce platelet aggregation, thereby reducing or avoiding the generation of blood viscosity and vascular embolism.
Through literature search, products which are identical or similar to the patent in terms of formula, preparation method and application are not reported.
Disclosure of Invention
Technical problem to be solved
Aiming at the defects of the prior art, the invention provides a biological component composition for improving blood viscosity and blood vessel embolism, which has the advantages of remarkably reducing serum cholesterol and triglyceride, lowering blood pressure, enhancing cardio-cerebral blood supply, softening blood vessels, reducing platelet aggregation and the like, and solves the problems of blood viscosity and blood vessel embolism.
(II) technical scheme
In order to achieve the purpose, the invention provides the following technical scheme: a biological component composition for improving blood viscosity and blood vessel embolism comprises the following active component raw materials in parts by weight according to daily dosage: 1-20 parts of acer truncatum buge oil microcapsule powder, 1-20 parts of earthworm extract, 1-20 parts of natto, 0.1-5 parts of astaxanthin (haematococcus pluvialis), 0.1-1 part of yeast beta-glucan, 0.02-1.2 parts of vitamin C, 0.5-6 parts of astragalus root and angelica sinensis extract, and also comprises auxiliary materials accounting for 0-20 percent of the total weight of the active ingredient raw materials, and the oral preparation is prepared by a specific process.
Preferably, in the astragalus mongholicus and angelica sinensis extract, the crude drug ratio of the astragalus mongholicus to the angelica sinensis is 1:1.
Preferably, the raw materials are purchased from commercial raw materials except for the self-made acer truncatum seed oil microcapsule powder, the astragalus mongholicus and angelica sinensis extract and the earthworm extract, and the quality of the raw materials meets the requirements of national relevant food standards or Chinese pharmacopoeia.
Preferably, the auxiliary material can be one or more of cereal starch, potato starch, dextrin and sugar alcohol.
Preferably, the raw materials are purchased from commercial raw materials except for the acer truncatum seed oil microcapsule powder, the astragalus mongholicus and angelica sinensis extract and the earthworm extract, and are qualified according to standard inspection and have the particle size of 100 meshes.
Preferably, the oral preparation includes, but is not limited to, solid beverage, tablet, capsule, liquid beverage.
Preferably, the application is in improving blood viscosity and blood vessel embolism.
Preferably, it is used in improving blood viscosity and other blood rheological parameters, chronic arterial embolism and chronic deep vein embolism.
The biological component combination formula for improving blood viscosity and blood vessel embolism is determined by taking the traditional Chinese medicine and modern biotechnology theories as guidance on the basis of laboratory research and experimental population, and the basic basis of the formula is as follows:
1. acer truncatum seed oil microcapsule powder
Acer truncatum seed oil contains unsaturated fatty acid more than 90%, nearly hundreds of natural nutrients such as oleic acid, linolenic acid and the like beneficial to human body, and particularly contains about 5.5% of natural cis-15-tetracosenic acid. Cis-15-tetracosenic acid is the only one double-effect miraculous substance which is recognized by scientists in various countries and can repair and dredge damaged nerve fibers and promote nerve cell regeneration. The growth factor can promote growth of the growth factor, has the functions of nourishing, repairing, regenerating and remodeling nerve cells, can protect vascular endothelium, repair vascular variant cells and necrosis factors, block deposition of blood peroxide on vascular walls and plaque formation, can treat heart and brain simultaneously, and has irreplaceable remarkable effect on blood viscosity and complicating cardiovascular and cerebrovascular diseases. The invention adopts acer truncatum seed oil microcapsule powder instead of new food raw material nervonic acid, because nervonic acid is a synthetic compound, the nervonic acid can have synthetic conditions at present, few production plants obtaining production permission are provided, the detection method is not clear and uniform, and a lot of nervonic acid water goods and fake goods are sold on the market, so that the quality of the raw materials is difficult to ensure. In addition, the synthesized nervonic acid does not contain other rich natural components except cis-15-tetracosenoic acid in acer truncatum seed oil, and in contrast, acer truncatum seed oil and the microcapsule powder prepared from the acer truncatum seed oil are beneficial and are a characteristic of raw material selection.
2. Earthworm extract
The invention adopts earthworm (Eisenia foetida) to prepare the earthworm extract by extraction, concentration, drying and sterilization. Earthworm protein is not adopted because the earthworm protein is mainly protein (protein is more than or equal to 65 percent, lumbrokinase cannot be detected) and does not contain other components except the protein in the earthworm, and the effect is far less than that of the earthworm extract through the verification of a comparative test. The extract of earthworm prepared by a specific process preserves the components of plasmin, lumbrokinase, collagenase, nucleic acid, trace elements and the like contained in the earthworm. Has effects in inhibiting platelet aggregation, promoting thrombolysis, improving microcirculation and collateral circulation of blood vessel, and increasing blood flow. Has definite biological activity for improving blood rheology index, coronary heart disease, angina pectoris, cerebral infarction, etc. The earthworm extract is also a feature of the raw material selection of the invention.
3. Natto
The soybean is prepared by fermenting with bacillus subtilis. Contains rich nutrients such as saponin, isoflavone, enzymes, viable Bacillus natto, unsaturated fatty acid, lecithin, folic acid, calcium, ferrum, potassium, vitamins, various amino acids, minerals, etc. Especially contains special components of nattokinase and vitamin K2, and researches prove that the natto has the health-care effects of dissolving thrombus, resisting inflammation, resisting bacteria, resisting aging and regulating physiological functions. The product can also be prepared by fermenting bean micropowder with Bacillus subtilis.
4. Astaxanthin
Astaxanthin is a carotenoid from haematococcus pluvialis, is 'antioxidative king' (6000 times of VC) in the nature, can penetrate through cell membranes and blood brain barriers, can remove free radicals, can reduce cholesterol, can protect blood vessels and nerves, and plays a vital role in resisting oxidative stress of cardiovascular and cerebrovascular systems.
5. Yeast beta-glucans
The saccharomyces cerevisiae is used as a raw material and is produced by extraction, acid-base treatment, spray drying and the like. Natural and safe, and high bioactivity. Has effects in resisting radiation, neutralizing chemical toxin, removing toxin, regulating blood lipid, preventing coronary heart disease, arteriosclerosis, apoplexy, resisting tumor, hepatitis B virus, rheumatic disease, autoimmune disease, regulating blood sugar, and protecting and repairing pancreatic islet beta-cell. Can provide multiple cell growth factors and repair the damaged cells of blood vessels.
6. Vitamin C
Can remove super negative oxygen ions, relieve toxic and harmful effects of lead, arsenic, mercury and the like, enhance the anti-stress capability and immunity of the body to the external environment, improve the metabolism of fat, improve the utilization of folic acid, calcium and iron, promote the synthesis of ossein and antibodies, and be beneficial to constructing the healthy intravascular environment.
7. Extract of radix astragali and radix Angelicae sinensis
Radix astragali has effects of invigorating vital qi, strengthening spleen and stomach, and promoting blood circulation. Dang Gui can tonify blood, activate blood, moisten intestines to relieve constipation. The combination of the astragalus root and the angelica with the earthworm in the formula is a wonderful combination. The earthworms have channeling property and can dredge collaterals; radix astragali has effects of invigorating qi, nourishing blood, and promoting qi circulation; the angelica has the effects of promoting blood circulation, removing blood stasis and enriching blood, and the three are matched to enhance the effects of promoting blood circulation, dredging collaterals, tonifying qi and nourishing blood, and has synergistic effect on improving blood viscosity and complicating cardiovascular and cerebrovascular diseases.
Although the raw materials in the formula are used singly and have the functions of adjusting the blood viscosity and the probability of the occurrence of complications to different degrees, the emphasis, the action mechanism, the use amount and the compatibility contraindication of each raw material are different. The formula is determined in the process of a large number of experiments, and the inventor surprisingly discovers that the components have obvious synergistic interaction after the raw materials are compatible for use, and the 1+1>2 effect is generated. High utilization rate of raw materials and obvious effect of improving and adjusting blood viscosity and complicating diseases. Toxicological tests of the formulation also indicate that it is safe.
Compared with the prior art, the invention provides a biological component composition for improving blood viscosity and vascular embolism, and the biological component composition has the following beneficial effects:
1. the biological component combination for improving blood viscosity and blood vessel embolism is a four-in-one scientific formula consisting of an antioxidant component, an anticoagulant component, a fibrinolytic component and a qi and blood tonifying component, has four efficacies of clearing (removing blood rubbish), regulating (regulating high risk factors of cardiovascular and cerebrovascular diseases), dissolving (tracing and dissolving thrombus) and tonifying (activating blood and tonifying qi), improves blood viscosity in multiple ways and multiple mechanisms, prevents and treats blood vessel embolism, is scientific and unique in formula, has broken tonifying effect, clear mechanism, synergistic effect and prominent comprehensive function, fundamentally improves blood viscosity and blood vessel embolism, and has substantial novelty and creativity compared with the prior art.
2. The biological component combination for improving blood viscosity and blood vessel embolism has definite effect on improving blood coagulation, viscosity and thickening, has actual effect on chronic arterial embolism and chronic deep venous embolism, provides a barrier for reducing the incidence of coronary heart disease and cerebral apoplexy, has substantial technical progress, and has great significance for human health.
3. The biological component composition for improving blood viscosity and vascular embolism has the advantages of large market demand, easily available raw materials, dual purposes of medicine and food, high use safety, simple preparation process and no need of more investment, and the implementation of the technical scheme has good economic benefit and social benefit.
(III) detailed description of the preferred embodiments
The technical solutions in the embodiments of the present invention will be clearly and completely described below, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all embodiments. All other embodiments, which can be obtained by a person skilled in the art without making any creative effort based on the embodiments in the present invention, belong to the protection scope of the present invention.
Example one
This example is a specific embodiment of a combination of biological components to improve blood viscosity and vascular embolization.
A biological component composition for improving blood viscosity and blood vessel embolism comprises the following active component raw materials in parts by weight according to daily dosage: 1-20 parts of acer truncatum buge oil microcapsule powder, 1-20 parts of earthworm extract, 1-20 parts of natto, 0.1-5 parts of astaxanthin (haematococcus pluvialis), 0.1-1 part of yeast beta-glucan, 0.02-1.2 parts of vitamin C, 0.5-6 parts of astragalus root and angelica sinensis extract, and also comprises auxiliary materials accounting for 0-20 percent of the total weight of the active ingredient raw materials, and the oral preparation is prepared by a specific process.
Specifically, in the astragalus and angelica extract, the crude drug ratio of the astragalus to the angelica is 1:1.
Specifically, the raw materials except the acer truncatum seed oil microcapsule powder, the astragalus mongholicus and angelica sinensis extract and the earthworm extract are self-prepared and are purchased from commercial raw materials, and the quality of the raw materials meets the requirements of national relevant food standards or Chinese pharmacopoeia.
Specifically, the adjuvants can be one or more of cereal starch, potato starch, dextrin, and sugar alcohol.
Specifically, the raw materials except the acer truncatum seed oil microcapsule powder, the astragalus mongholicus and angelica sinensis extract and the earthworm extract are self-prepared and are all purchased from commercial raw materials, and the raw materials are qualified according to standard inspection and have the particle size of 100 meshes.
In particular, oral formulations include, but are not limited to, solid beverages, tablets, capsules, liquid beverages.
In particular to the application in improving blood viscosity and blood vessel embolism.
In particular, it is applied to improving blood viscosity and other blood rheological parameters, chronic arterial embolism and chronic deep vein embolism.
Example two
This example is a specific implementation of an optimized protocol for the combination of biological components to improve blood viscosity and vascular embolization.
An optimized scheme of biological component combination for improving blood viscosity and vascular embolism comprises the following active component raw materials in parts by weight according to daily dosage: 2.8-3 parts of acer truncatum buge oil microcapsule powder, 1.7-2.3 parts of earthworm extract, 1.5-2 parts of natto, 0.4-0.5 part of astaxanthin (haematococcus pluvialis), 0.1-0.2 part of yeast beta-glucan, 0.1-0.2 part of vitamin C, 1.9-2 parts of astragalus mongholicus and angelica sinensis extract and also comprises auxiliary materials accounting for 0-20 percent of the total weight of the active ingredient raw materials, and the oral preparation is prepared by a specific process.
EXAMPLE III
This example is a more suitable embodiment of a combination of biological components to improve blood viscosity and vascular embolization.
The scheme is characterized by comprising the following active ingredient raw materials in parts by weight according to daily dosage: 2 parts of acer truncatum buge oil microcapsule powder, 2.2 parts of earthworm extract, 2 parts of natto, 0.5 part of astaxanthin (haematococcus pluvialis), 0.25 part of yeast beta-glucan, 0.2 part of vitamin C, 1.85 parts of astragalus mongholicus and angelica sinensis extract, and also comprises auxiliary materials accounting for 0-20% of the total weight of active ingredient raw materials, and the oral preparation is prepared by a specific process.
Example four
This example is a specific implementation of the preparation method of acer truncatum seed oil microcapsule powder.
The preparation method of the acer truncatum seed oil microcapsule powder comprises the following steps:
s1, weighing the modified starch and water according to the proportion of 1:1.5, and adding the modified starch and water into normal-temperature water for dissolving to form modified starch slurry;
s2, weighing the acer truncatum seed oil and the modified starch according to the ratio of 1:1.5, adding the acer truncatum seed oil and the modified starch into the modified starch slurry, and carrying out high-speed shearing for 10 minutes at the rotating speed of a shearing machine (17000 r/min);
s3, placing the sheared emulsion into a homogenizer, homogenizing for 2 times under the pressure of the homogenizer (10kpa/c square meter) to obtain homogenized emulsion, drying the homogenized emulsion at the temperature of below 50 ℃, and crushing to obtain the acer truncatum seed oil microcapsule powder.
EXAMPLE five
This example is a specific embodiment of the method for preparing the extract of astragalus and angelicae sinensis.
The preparation method of the astragalus and angelica extract comprises the following steps:
s1, crushing astragalus and angelica into 20 meshes, and soaking the crushed astragalus and angelica in 70% ethanol in an amount which is 8 times that of the crushed angelica for 4 hours;
s2, heating, refluxing and extracting for 2 times, wherein each time is 1.5 hours, and the temperature is 70 ℃;
s3, mixing the filtrates, recovering ethanol, concentrating the precipitate to 1.15, oven drying at below 70 deg.C, and pulverizing.
EXAMPLE six
This example is a specific embodiment of a method for producing an earthworm extract.
The preparation method of the earthworm extract comprises the following steps:
s1, cleaning earthworms, and removing impurities from the earthworms and cleaning;
s2, breaking the wall of the earthworms, soaking the cleaned earthworms in normal saline with the volume ratio of the earthworms to the normal saline being 1:1.5-2, breaking the wall of the earthworms after soaking for 20-30 minutes, and filtering to remove the horny layer of the earthworms to obtain earthworm liquid; removing salt from the earthworm liquid through a permeable membrane;
s3, extracting, namely adding acetic acid solution into the earthworm liquid, fully mixing the earthworm liquid and the acetic acid solution according to the volume ratio of 1:2-3 to obtain mixed liquid, extracting for 30 minutes, controlling the temperature to be 60 ℃, and filtering filtrate;
s4, concentrating, performing rotary evaporation on the mixed solution, and concentrating to obtain a concentrated solution;
s5, drying, and drying the concentrated solution to obtain extract powder;
s6, sterilizing, and sterilizing the extract powder to obtain the edible earthworm extract.
EXAMPLE seven
The embodiment is a specific implementation mode of a preparation method of a solid beverage preparation of biological component combination for improving blood viscosity and blood vessel embolism.
A preparation method of a solid beverage preparation of a biological component combination for improving blood viscosity and blood vessel embolism comprises the following steps:
s1, the weight portions of the following raw materials are:
2.8kg of acer truncatum buge oil microcapsule powder, 1.7kg of earthworm extract, 1.5kg of natto, 0.4-kg of astaxanthin (haematococcus pluvialis), 0.1kg of yeast beta-glucan, 0.1kg of vitamin C, 1.9kg of astragalus mongholicus and angelica sinensis extract and 1.5kg of corn starch.
S2, the preparation method comprises the following steps: weighing raw materials, mixing for 1 hour, drying at 60 deg.C to water content of less than or equal to 5%, packaging, inspecting, packaging, and warehousing.
Example eight
This example is a specific embodiment of a method for preparing a tablet formulation of a combination of biological ingredients for improving blood viscosity and vascular embolization.
A preparation method of a tablet preparation of a biological component combination for improving blood viscosity and blood vessel embolism comprises the following steps:
s1, the weight portions of the following raw materials are:
3kg of acer truncatum buge oil microcapsule powder, 2.3kg of earthworm extract, 2kg of natto, 0.5kg of astaxanthin (haematococcus pluvialis), 0.2kg of yeast beta-glucan, 0.2kg of vitamin C, 2kg of astragalus mongholicus and angelica sinensis extract and 0.2kg of corn starch;
s2, the preparation method comprises the following steps: the raw materials are qualified through inspection, weighed, mixed for 1 hour, granulated by 16 meshes, dried at the temperature of 60 ℃ to ensure that the moisture is less than or equal to 5 percent, pressed into tablets, dried in the air, subpackaged, inspected, packaged and warehoused to obtain the finished product.
Example nine
This example is a specific embodiment of a method for preparing a capsule containing a combination of biological ingredients for improving blood viscosity and vascular embolization.
A preparation method of a tablet capsule preparation of biological component combination for improving blood viscosity and blood vessel embolism comprises the following steps:
the weight portions of the following raw materials are as follows:
s1, 2kg of acer truncatum oil microcapsule powder, 2.2kg of earthworm extract, 2kg of natto, 0.5kg of astaxanthin (haematococcus pluvialis), 0.25kg of yeast beta-glucan, 0.2kg of vitamin C, 1.85 kg of astragalus and angelica extract and 1kg of corn starch;
s2, the preparation method comprises the following steps: the raw materials are qualified by inspection, weighed, mixed for 1 hour, granulated by 16 meshes, dried at the temperature of 60 ℃ to ensure that the water content is less than or equal to 5 percent, filled into capsules, subpackaged, inspected, packaged and warehoused to obtain the capsule.
Example ten
This example is a specific embodiment of a method for preparing a liquid beverage formulation with a combination of biological ingredients that improves blood viscosity and vascular embolization.
A method for preparing a liquid beverage preparation containing a combination of biological components for improving blood viscosity and blood vessel embolism comprises the following steps:
s1, weighing and mixing the formula raw materials, and adding 90% of purified water;
s2, stirring, packaging, sterilizing, and making into liquid beverage.
Examples of the experiments
The product for improving blood viscosity and blood vessel embolism reduces the blood viscosity and improves the effect record of complications.
Tracking the number of observed people: 20 of the Chinese patent medicines: 8 men and 12 women, age 44-78 years.
Tracking and observing conditions: the past history of hypertension, hyperlipidemia, hyperglycemia, coronary heart disease and cerebral apoplexy with blood hyperviscosity and complication is 3-5 years, and a hospital has a diagnostic book within one year.
The treatment method comprises the following steps: the product of example 4 was used, one bag per day; the administration is continued for 20-72 days and the results are recorded.
Tracking follow-up visit: for the test persons to follow up one by one, the detailed inquiry, physical examination and examination of the detection report within 10 days are carried out, and the following follow-up results are as follows:
statistical result of follow-up visit for experimental case tracking
Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that changes, modifications, substitutions and alterations can be made in these embodiments without departing from the principles and spirit of the invention, the scope of which is defined in the appended claims and their equivalents.
Claims (8)
1. A biological component composition for improving blood viscosity and blood vessel embolism is characterized in that: the composition comprises the following active ingredient raw materials in parts by weight: 1-20 parts of acer truncatum buge oil microcapsule powder, 1-20 parts of earthworm extract, 1-20 parts of natto, 0.1-5 parts of astaxanthin (haematococcus pluvialis), 0.1-1 part of yeast beta-glucan, 0.02-1.2 parts of vitamin C, 0.5-6 parts of astragalus root and angelica sinensis extract, and also comprises auxiliary materials accounting for 0-20 percent of the total weight of the active ingredient raw materials, and the oral preparation is prepared by a specific process.
2. The biological component combination for improving blood viscosity and blood vessel embolism according to claim 1, wherein: in the astragalus and angelica extract, the crude drug ratio of the astragalus to the angelica is 1:1.
3. The biological component combination for improving blood viscosity and blood vessel embolism according to claim 1, wherein: the raw materials are self-prepared except for acer truncatum seed oil microcapsule powder, astragalus mongholicus and angelica sinensis extract and earthworm extract, are purchased from commercial raw materials, and the quality of the raw materials meets the requirements of national relevant food standards or Chinese pharmacopoeia.
4. The biological component combination for improving blood viscosity and blood vessel embolism according to claim 1, wherein: the adjuvants can be one or more of cereal starch, potato starch, dextrin, and sugar alcohol.
5. The biological component combination for improving blood viscosity and blood vessel embolism according to claim 1, wherein: the raw materials are all purchased from commercial raw materials except for acer truncatum seed oil microcapsule powder, astragalus mongholicus and angelica sinensis extract and earthworm extract, and are qualified according to standard inspection and have the particle size of 100 meshes.
6. The biological component combination for improving blood viscosity and blood vessel embolism according to claim 1, wherein: the oral preparation includes but is not limited to solid beverage, tablet, capsule and liquid beverage.
7. The biological component combination for improving blood viscosity and blood vessel embolism according to claim 1, wherein: is applied to improving blood viscosity and blood vessel embolism.
8. The combination of biological components for improving blood viscosity and vascular embolization according to claim 1, wherein: it is used in improving blood viscosity and other blood rheological parameters, chronic arterial embolism and chronic deep vein embolism.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210199790.5A CN114588194A (en) | 2022-03-01 | 2022-03-01 | Biological component composition for improving blood viscosity and blood vessel embolism |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210199790.5A CN114588194A (en) | 2022-03-01 | 2022-03-01 | Biological component composition for improving blood viscosity and blood vessel embolism |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114588194A true CN114588194A (en) | 2022-06-07 |
Family
ID=81814766
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210199790.5A Pending CN114588194A (en) | 2022-03-01 | 2022-03-01 | Biological component composition for improving blood viscosity and blood vessel embolism |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114588194A (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102406115A (en) * | 2011-10-26 | 2012-04-11 | 江苏江大源生态生物科技有限公司 | Natural functional food for preventing cardiovascular and cerebrovascular diseases |
CN108310044A (en) * | 2018-03-26 | 2018-07-24 | 刘莹艳 | A kind of Chinese medicine of relaxing tendons and activating collaterals and preparation method thereof |
CN109645295A (en) * | 2019-01-17 | 2019-04-19 | 云南龙布瑞生物科技有限公司 | A kind of Astaxanthin In Haematococcus Pluvialis solid beverage maintaining cardiovascular system health |
-
2022
- 2022-03-01 CN CN202210199790.5A patent/CN114588194A/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102406115A (en) * | 2011-10-26 | 2012-04-11 | 江苏江大源生态生物科技有限公司 | Natural functional food for preventing cardiovascular and cerebrovascular diseases |
CN108310044A (en) * | 2018-03-26 | 2018-07-24 | 刘莹艳 | A kind of Chinese medicine of relaxing tendons and activating collaterals and preparation method thereof |
CN109645295A (en) * | 2019-01-17 | 2019-04-19 | 云南龙布瑞生物科技有限公司 | A kind of Astaxanthin In Haematococcus Pluvialis solid beverage maintaining cardiovascular system health |
Non-Patent Citations (1)
Title |
---|
聂克: "黄芪当归药对对心血管系统作用的研究概况", 《中国中西医结合杂志》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8927523B2 (en) | Compound sea cucumber preparation and manufacturing method thereof | |
US20170128514A1 (en) | Pharmaceutical composition for treating cardio-cerebrovascular diseases and method for preparing the same | |
CN101724667A (en) | Technology for extracting dendrobium polysaccharide by applying biology engineering enzyme technology and product thereof and application | |
CN107184966A (en) | A kind of pharmaceutical composition for preventing and treating diabetes and its complication | |
CN112961262A (en) | Passiflora edulis pericarp acidic polysaccharide, preparation method and application thereof | |
CN105341893A (en) | Composition for assisting in reducing blood glucose and application | |
CN104857154A (en) | Traditional Chinese medicine composition for treating three-high diseases and preparation method therefor | |
CN101664180A (en) | Health-care nutritional complexing agent with effect of and preparation method thereof | |
CN111743924A (en) | Marine plant extract for treating diabetes, composition and application | |
CN106362142A (en) | Formula composition capable of reducing blood pressure | |
CN106509894A (en) | Moringa oleifera and pseudo-ginseng buccal tablets and preparation technology thereof | |
CN114588194A (en) | Biological component composition for improving blood viscosity and blood vessel embolism | |
CN104922295A (en) | Blood-nourishing and blood-enriching traditional Chinese medicine composition | |
CN105433260A (en) | Health-care food for reducing blood fat and preparation process thereof | |
CN107927764A (en) | A kind of health food containing sea cucumber extract and earthworm albumen powder and preparation method thereof | |
AU2021100051A4 (en) | Antitumor formula and extraction method thereof | |
CN111000237A (en) | Dietary composition for dietary intervention of cardiovascular and cerebrovascular diseases and preparation method thereof | |
CN110638988A (en) | Preparation method of plant cell zymolyte for killing human herpes zoster virus | |
CN111729056A (en) | Anticancer medicine composition and its prepn | |
CN103494978B (en) | Method for preparing freeze-dried powder injection for treating liver ascitic tumor by using aloe and lucid ganoderma | |
CN108420842A (en) | A kind of sowthistle-leaf ixeris seedling preparation of antigout effect | |
CN103055011A (en) | G6 lectin extracted from traditional Chinese medicines and applications thereof in detoxification, pressure stabilization, blood vessel softening and complication resistance | |
CN113491331B (en) | Algal polysaccharide composition and compound fruit juice mixed fermentation powder as well as preparation method and application thereof | |
CN108452047B (en) | Composition for delaying senility, inhibiting growth of tumor cells and improving cardiovascular and cerebrovascular microcirculation | |
CN107412607B (en) | Asparagus capsule and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20220607 |
|
WD01 | Invention patent application deemed withdrawn after publication |